Organon & Co. (OGN)
| Market Cap | 3.62B +52.0% |
| Revenue (ttm) | 6.13B -2.5% |
| Net Income | 209.00M -70.1% |
| EPS | 0.79 -70.5% |
| Shares Out | 262.61M |
| PE Ratio | 17.38 |
| Forward PE | 3.82 |
| Dividend | $0.08 (0.58%) |
| Ex-Dividend Date | Aug 14, 2026 |
| Volume | 3,160,791 |
| Open | 13.75 |
| Previous Close | 13.75 |
| Day's Range | 13.75 - 13.78 |
| 52-Week Range | 5.69 - 13.83 |
| Beta | 1.54 |
| Analysts | Hold |
| Price Target | 10.33 (-25.04%) |
| Est. Earnings | Nov 9, 2026 |
About OGN
Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women’s health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregnancy; Follistim AQ, which is used to promote develo... [Read more]
Financial Performance
In 2025, Organon & Co.'s revenue was $6.22 billion, a decrease of -2.92% compared to the previous year's $6.40 billion. Earnings were $187.00 million, a decrease of -78.36%.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for OGN stock is "Hold." The 12-month stock price target is $10.33, which is a decrease of -25.04% from the latest price.
News
Organon to Report Third Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, plans to release its third q...
Organon to present interim Phase 3 study results for MIUDELLA
Organon (OGN) announced that Sebela Women’s Health will present interim results from an ongoing Phase 3 study evaluating MIUDELLA, a hormone-free, copper intrauterine device, through 6 years of use at...
Organon Announces Positive Interim Phase 3 Study Results for MIUDELLA®, a Hormone-Free, Intrauterine Device (IUD), Through 6 Years of Use to Be Presented at the 2026 Society of Family Planning Annual Meeting
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon reports positive interim Phase 3 results for MIUDELLA®, a hormone-free IUD, through 6 years of use with no new safety signals.
Organon to Present New Real-World Analysis of VTAMA® (tapinarof) Cream, 1%, at the 2026 Fall Clinical Dermatology Conference
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon to unveil first large-scale real-world effectiveness analyses of VTAMA (tapinarof) cream, 1% in patients with eczema at Fall Clinical.
Organon announces U.S. FDA accepted for review Sebela’s sNDA for Miudella
Organon (OGN) announced the US Food and Drug Administration, FDA, has accepted for review Sebela Women’s Health’s supplemental New Drug Application, sNDA, for Miudella for an extended duration of use…
Organon Announces US FDA Has Accepted for Review a Supplemental New Drug Application for MIUDELLA®, a Hormone-Free Intrauterine Device
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon announces FDA accepts MIUDELLA® sNDA for review, seeking to extend approved hormone-free IUD use from 3 to 6 years in the U.S.
National Can-RISE Study to Help Close Critical Gaps in Menopause Research
TORONTO, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Women's Health Collective Canada (WHCC) and the Partnership for Women's Health Research Canada (PWHR), in partnership with GreenShield and supported by a cha...
Organon opens REMS Program for Miudella
Organon (OGN) announced the Miudella Risk Evaluation and Mitigation Strategy, REMS, Program is now open for enrollment on its website. The website enables healthcare providers, healthcare settings, an...
Organon Opens REMS Program for MIUDELLA® Ahead of Anticipated Commercial Availability
JERSEY CITY, N.J.--(BUSINESS WIRE)--HCPs, healthcare settings and pharmacies can begin REMS certification for Organon's hormone-free copper IUD, MIUDELLA, ahead of upcoming launch.
Organon & Co. Quarterly report: Q2 2026
Organon & Co. has published its Q2 2026 quarterly earnings report on July 31, 2026.
Organon Announces Quarterly Dividend
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that the com...
Organon to present results from analysis of Phase 3 trials of VTAMA cream
Organon (OGN) will present results from a post hoc analysis of pooled data from the Phase 3 pivotal trials, ADORING 1 and ADORING 2, evaluating the efficacy and safety of…
New Analysis of Phase 3 Pooled Data for Organon's VTAMA® (tapinarof) cream, 1%, Demonstrates Early, Consistent Improvements in Atopic Dermatitis Patients Across Pediatric Age Groups and in Adults1
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon Presents VTAMA (tapinarof) cream, 1% Analysis of Phase3 Pooled Data Showing Early Consistent Improvements in Eczema Patients Across Age Groups.
Organon & Co. Transcript: EGM 2026
Shareholders approved the merger with Sun Pharma USA and the related executive compensation proposal. Quorum was established, and all formal procedures were followed. Final voting results will be filed with the SEC.
Organon & Co. Proxy statement: Proxy filing
Organon & Co. filed a proxy statement on July 17, 2026, providing details for shareholder voting and corporate governance matters.
Organon to Report Second Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, plans to release its second ...
Organon Canada and Henlius Expand Access to Denosumab Treatments With Launch of BILDYOS® (denosumab injection) and TUZEMTY® (denosumab injection), Biosimilars to PROLIA and XGEVA
KIRKLAND, Quebec & SHANGHAI--(BUSINESS WIRE)--Organon Canada and Henlius expand access to denosumab treatments with launch of BILDYOS® and TUZEMTY® biosimilars to PROLIA and XGEVA.
Organon completes agreement to license MIUDELLA hormone-free IUD
Organon (OGN) announced the completion of a global licensing agreement with Sebela Pharmaceuticals, granting Organon exclusive rights to MIUDELLA, a hormone-free, copper intrauterine device. Approved ...
Organon Completes Agreement to License MIUDELLA®, Sebela Pharmaceuticals' Hormone-Free Intrauterine Device
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon completes agreement to license MIUDELLA®, Sebela's hormone-free IUD, expanding its long-acting reversible contraception portfolio.
Organon and Samsung Bioepis expand commercialization agreement for Pyzchiva
Samsung Bioepis and Organon (OGN), a global healthcare company with expertise in biosimilars, announced the expansion of their development and commercialization agreement, whereby Organon will obtain ...
Organon and Samsung Bioepis Expand Agreement to Commercialize PYZCHIVA® (ustekinumab), a Biosimilar Referencing STELARA® (ustekinumab) in Canada
INCHEON, South Korea & KIRKLAND, Quebec--(BUSINESS WIRE)--Organon and Samsung Bioepis expand agreement to commercialize PYZCHIVA® (ustekinumab), a biosimilar referencing STELARA® (ustekinumab) in Cana...
Organon & Co. Proxy statement: Proxy filing
Organon & Co. filed a proxy statement on June 17, 2026, providing details for shareholder voting and corporate governance matters.
Organon & Co. Proxy statement: Proxy filing
Organon & Co. filed a proxy statement on June 11, 2026, providing details for shareholder voting and corporate governance matters.
Organon wins US approval to widen use of arthritis biosimilar drug
Organon said on Wednesday the U.S. Food and Drug Administration has approved the expanded use of its arthritis drug, a biosimilar to Roche's Actemra, to treat a life‑threatening immune reaction in s...
Organon announces U.S. FDA approval pf sBLA for Tofidence injection
Organon (OGN) announced the US Food and Drug Administratio, FDA, approval of the supplemental Biologics License Application, sBLA, for Tofidence injection, for intravenous use, a biosimilar to Actemra...